Join Conscio Group upcoming webinar on December 12 at 2:00 PM CET (expected length up to 2 hours), where industry experts will discuss the latest trends in regulation, R&D and clinical testing. In our session we will particularly explore potential regulatory changes regarding the waiver of Phase 3 efficacy studies.

Topics include:

  • Navigating Biosimilar Regulations: Evolution, Challenges, and Future Directions
  • Common pitfalls on the path from R&D to biotech product commercialization
  • Strategies for successful bioassay transfer and validation – the importance of standardization

Speakers: Elena Guillen Benitez, MD, PhD from Leiden University Medical Center, Martin Baur from Midas Pharma, and Klemens Weitenthaler from Conscio Group.

Moderator: Stephan Holl, CEO Conscio Group

Gain insider knowledge on the biosimilar industry – register here!

If you would like to view the recording of the webinar, please contact us today and we will be happy to give you exclusive access to it on our YouTube channel.

Additional News

  • 5 srpna 2025

    Preclinical Bioanalysis That Accelerates Clinical Entry

    How fit-for-purpose and GLP-compliant bioanalysis can streamline your path to IND and CTA approvals.

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.

ALL POSTS